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Abstract. TheWorld Health Organization haswarned that substandard and falsiﬁedmedical products (SFs) can harm
patients and fail to treat thediseases forwhich theywere intended, and theyaffect every regionof theworld, leading to loss
of conﬁdence in medicines, health-care providers, and health systems. Therefore, development of analytical procedures
to detect SFs is extremely important. In this study, we investigated the quality of pharmaceutical tablets containing the
antihypertensive candesartan cilexetil, collected in China, Indonesia, Japan, and Myanmar, using the Japanese phar-
macopeial analytical procedures for quality control, togetherwith principal component analysis (PCA) of Ramanspectrum
obtained with handheld Raman spectrometer. Some samples showed delayed dissolution and failed to meet the phar-
macopeial speciﬁcation, whereas others failed the assay test. These products appeared to be substandard. Principal
component analysis showed that all Raman spectra could be explained in terms of two components: the amount of the
active pharmaceutical ingredient and the kinds of excipients. Principal component analysis score plot indicated one
substandard, and the falsiﬁed tablets have similar principal components in Raman spectra, in contrast to authentic
products. The locations of samples within the PCA score plot varied according to the source country, suggesting that
manufacturers in different countries use different excipients. Our results indicate that the handheld Raman device will be
useful for detection of SFs in the ﬁeld. Principal component analysis of that Raman data clarify the difference in chemical
properties between good quality products and SFs that circulate in the Asian market.
INTRODUCTION
InMay 2017, deﬁnition of substandard and falsiﬁedmedical
products (SFs) was announced by the World Health Organi-
zation.1 Substandard medical products (also called “out of
speciﬁcation”) are authorized by national regulatory authori-
ties but fail to meet either national or international quality
standards or speciﬁcations, or in some cases, both. On the
other hand, falsiﬁed medical products deliberately or fraudu-
lently misrepresent their identity, composition, or source.1–5
Many surveys of falsiﬁed medical products and analytical
procedures for investigation of the authenticity of medical
products have been reported by various public institutes.2–12
In 2015, the Pharmaceutical Security Research Institute re-
ported that Asia experienced the highest incidence of drug
crime cases among seven regions in the world. In that year, a
total of 3,002 cases of drug crime cases were recorded,
amongwhich around 1,000 involved theAsia-Paciﬁc region.13
Many cases where defective products have been transported
across national borders have been reported.14
Relatively little work has been carried out on analytical meth-
ods for investigating the actual status of substandard medical
products, including their distribution, and their physical and
chemical properties.14,15 One reason for this maybe concern
about thepossibility of excessively hindering thedevelopmentof
medicines and access to medicines in developing countries.16
Also, regular quality control and surveillance of medicines after
marketing tend to be more difﬁcult in developing countries for
various reasons, including high cost, the need for sophisticated
equipment and skilled technicians, and lack of pharmaco-
logical knowledge to recognize the need for implementation
of countermeasures.6,15,17–19 Furthermore, medicines may
be transported across national borders without proper quality
checks through various distribution channels.14,20 These are
serious issues tobe takenmeasureof, becauseSFscancause
treatment failure, development of antimicrobial resistance,
and serious adverse drug reactions, thereby damaging public
conﬁdence in medicines.2,21,22
The International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH) Q6A
provides guidance to establish a harmonized set of global
speciﬁcations consisting of analytical procedures and accep-
tance criteria for new drug substances (DS) and drug products
(DP) for human use (1999).23 Speciﬁcations of DS and DP are
proposed and justiﬁed by the manufacturer, and approved by
regulatory authorities in each country. The speciﬁcations and
acceptance criteria are focused on those chemical, physi-
cal, and biological properties considered to be important for
ensuring the safety and efﬁcacy of DS and DP. Thus, they
can be adopted to identify substandard products. Possible
issues include 1) out-of-speciﬁcation content of active
pharmaceutical ingredient (API),24,25 2) signiﬁcant dissolu-
tion delay,24 3) contamination with toxic substances,26,27
and 4) lack of sterility.28,29 These points can be checked by
means of assay, content uniformity testing, measurements
of dissolution properties and impurities, and microbial tests.
In this study, candesartan cilexetil tablets were collected in
China, Indonesia, Japan, and Myanmar and subjected to
quality control tests (assays, content uniformity, and disso-
lution tests) according to the Japanese pharmacopeia.30 The
acceptance criteria for these tests in the Japanese pharma-
copeia were adopted as thresholds for identiﬁcation of SFs.
* Address correspondence to TomokoKakio, Analytical Development,
Pharmaceutical Sciences, Takeda Pharmaceutical Company, Ltd.,
Osaka, Japan. E-mail: tomoko.kakio@takeda.com
1643
Many issues of quality and bioavailability are considered to
be due to technical deﬁciencies in the manufacturing process
design and differences in the nature of the excipients.31–33
Although many studies have shown that excipients inﬂuence
quality, the excipients are not generally stipulated in quality
tests.Our previous study found that the typesof the excipients
used in candesartan cilexetil tablets differ depending on the
manufacturer, and Raman spectra of the tablets showed the
different pattern reﬂecting the chemical nature of the excipi-
ents.34 Here, we focused on the methodology for detecting
substandard and falsiﬁed medicines by principal component
analysis (PCA)12,22,35–43 of raw data obtained by handheld
Raman spectroscopy. We aimed to clarify the chemical fea-
tures of substandard medicines by comparing them with au-
thentic medicines, and by extracting the principal components
of the Raman spectrum to visualize the relationships among
the tablets. We chose the handheld Raman device as a
simple spectroscope suitable for in situ observation in de-
veloping countries, and we used PCA as a mean to extract
critical information despite the limited resolution and sensi-
tivity of the device. We also compared signal preprocessing
methods of Raman spectra for PCA and selected the multi-
plicative scattering correlation (MSC) method as being par-
ticularly suitable to extract the desired signals from the
TABLE 1
Summary of collected samples from China, Indonesia, and Myanmar
No.
Product name stated
on the package Dose (mg)
Manufacturing country printed
on package Sampling area Sampling year Sampling facility
1–7 Blopress 8 Japan Shanghai, China 2012 Hospital 1–7
8–9 悉君宁 4 China Shanghai, China 2012 Hospital 8–9
10–11, 13 维尔亚 8 China Shanghai, China 2012 Hospital 10–11, 13
12 维尔亚 4 China Shanghai, China 2012 Hospital 12
14–26 XINXIN 4 China Shanghai, China 2012 Hospital 14–26
27–30 Candelong-8 8 India Mandalay, Myanmar 2015 Pharmacy A–D
31–33 Advant 8 Pakistan Mandalay, Myanmar 2015 Pharmacy E–G
34 Falsiﬁed product imitating Blopress 16 Indonesia Medan, Indonesia 2009 Pharmacy H
35, 37 Falsiﬁed product imitating Blopress 16 Indonesia Jakarta, Indonesia 2011–2012 Pharmacy I, J
36 Falsiﬁed product imitating Blopress 8 Indonesia Jakarta, Indonesia 2011 Pharmacy I
TABLE 2






















1 Blopress 8 99 1.9 3 Pass 103.9 0.4 3 Pass 0.7159
2 Blopress 8 86 0.6 3 Pass 102.7 3.3 3 Pass 0.5689
3 Blopress 8 95 0.4 3 Pass 104.0 0.4 3 Pass 0.6546
4 Blopress 8 95 0.4 3 Pass 100.5 0.1 3 Pass 0.6914
5 Blopress 8 93 2.2 2 Pass 101.2 0.6 3 Pass 0.6763
6 Blopress 8 90 1.8 3 Pass 99.9 0.7 3 Pass 0.5910
7 Blopress 8 88 1.3 3 Pass 101.1 1.7 3 Pass 0.6158
8 悉君宁 4 84 0.6 3 Pass 94.4 2.2 3 Fail 0.0000
9 悉君宁 4 86 3.1 3 Pass 94.4 2.1 3 Fail 0.0000
10 维尔亚 8 83 1.5 3 Pass 100.9 1.5 3 Pass 0.0000
11 维尔亚 8 81 4.1 3 Pass 103.5 4.8 3 Pass 0.0000
12 维尔亚 4 84 0.2 3 Pass 97.7 0.6 3 Pass 0.1483
13 维尔亚 8 81 4.0 3 Pass 103.7 0.8 3 Pass 0.0000
14 XINXIN 4 68 15.9 3 Fail 109.1 1.6 3 Fail 0.0000
15 XINXIN 4 88 3.8 3 Pass 108.7 1.8 3 Fail 0.0000
16 XINXIN 4 90 4.1 3 Pass 107.4 2.1 3 Fail 0.0000
17 XINXIN 4 85 1.0 3 Pass 104.4 2.5 3 Pass 0.0000
18 XINXIN 4 91 0.2 3 Pass 109.0 2.7 3 Fail 0.0000
19 XINXIN 4 90 4.4 3 Pass 110.3 0.4 3 Fail 0.0000
20 XINXIN 4 87 4.4 3 Pass 111.7 1.2 3 Fail 0.0000
21 XINXIN 4 83 1.2 3 Pass 107.2 4.8 3 Fail 0.0000
22 XINXIN 4 82 1.2 3 Pass 106.5 2.5 3 Fail 0.0000
23 XINXIN 4 89 3.1 3 Pass 105.1 1.8 3 Fail 0.0000
24 XINXIN 4 92 0.1 3 Pass 109.0 1.1 3 Fail 0.0000
25 XINXIN 4 63 13.3 3 Fail 112.8 4.0 3 Fail 0.0000
26 XINXIN 4 88 0.9 3 Pass 110.4 1.8 3 Fail 0.0000
27 Candelong-8 8 104 0.4 6 Pass 102.0 1.2 10 Pass 0.0337
28 Candelong-8 8 106 0.2 3 Pass 103.0 0.3 3 Pass 0.0969
29 Candelong-8 8 103 2.9 6 Pass 100.6 2.2 10 Pass 0.0457
30 Candelong-8 8 103 1.1 6 Pass 101.4 2.1 10 Pass 0.0302
31 Advant 8 95 2.9 6 Pass 93.3 3.8 10 Fail 0.1725
32 Advant 8 90 0.1 3 Pass 101.0 1.9 3 Pass 0.2416
33 Advant 8 92 1.8 6 Pass 97.0 3.0 10 Pass 0.1421
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strong ﬂuorescence background.43 This approach proved
highly effective to evaluate the degree of similarity among
samples.
EXPERIMENTAL
Sample collection. Authentic candesartan cilexetil tablets
(Blopress 4 mg, 8 mg and 12 mg) and placebo tablets in-
cluding the excipients same as Blopress except API were
supplied by a Japanese manufacturer (Takeda Pharmaceuti-
cal Company Ltd., Osaka, Japan) as the reference samples.
Samples of candesartan cilexetil tablets were collected from
the hospitals and clinics in China, Indonesia, and Myanmar
and also purchased via the internet (2009–2015). The falsiﬁed
products imitating Blopress discovered in Indonesia have
been reported to Forensics, Brand Protection, and Investi-
gations. These falsiﬁed products were identiﬁed based on
visual inspection of the packaging.34
Visual inspection. First, we observed the outer package
and package insert, Press Through Pack, or aluminum blister
packaging. Theproduct name, dose, component, formulation,
packaging unit, manufacturer, manufacturing date, expiration
date, and manufacturing number were recorded. The cartons
were examined visually and microscopically and compared
with reference samples. Printing on the edge of the tape seal
was carefully observed to check ﬁne details.
Quality control test. Content uniformity,44 assay, and dis-
solution tests of candesartan cilexetil tablets were conducted
according to Japanese pharmacopeia.30
Acetonitrile (for high-performance liquid chromatography
[HPLC]), polyoxyethylene 20, and sorbitan monolaurate (for
biochemistry) were purchased from Wako Pure Chemical In-
dustries, Ltd. (Osaka, Japan), acetic acid, and acenaphthene
were purchased fromNacalai Tesque Co., Ltd (Kyoto, Japan).
Content uniformity and assay. Candesartan cilexetil in
tabletswereextracted inamixtureofacetonitrileandwater (3:2)and
measurementswere carried out at awavelength of 305 nmusing a
spectrophotometer (U-3210,HITACHI,Tokyo,Japan).Becausethe
number of the collected samples was limited, two, three, or 10
tabletswere used for each evaluation of content uniformity and the
mean of the content was calculated as the result for assay. The
acceptancecriterionfor theassaywasset to95.0–105.0%assame
as the criterion in Japanese Pharmacopeia.30
Dissolution. The dissolution test was performed under the
condition described for Apparatus 2 (paddle method) with 50-
rpm agitation in 900 mL of a dissolution medium containing
FIGURE 1. Comparison of assay for the samples collected in China and Myanmar. Two vertical dashed lines show the acceptance criteria of
95.0–105.0% assay. This ﬁgure appears in color at www.ajtmh.org.
IDENTIFY SUBSTANDARD AND FALSIFIED TABLETS IN ASIAN COUNTRIES 1645
10 w/v% polyoxyethylene (20) sorbitan monolaurate at 37C.
A sample was taken at the time point of 45 minutes, and ex-
amined by high-speed liquid chromatography (HPLC, L-7200
autosampler, D-7000 interface, L-7100 pump, L-7300 col-
umn, L-7405 UV detector, HITACHI, Tokyo, Japan). Ace-
naphthene was added to the test solution as the internal
standard. High-performance liquid chromatography con-
ditions were as follows: 5-μm-octa decyl silyl (ODS) column
(Shim-pack CLC-ODS (M) 15 cm, SHIMADZU, Kyoto, Ja-
pan), a ﬂow rate of 1.8 mL/minute, a column temperature of
25C, an injection volume of 50 μL, a detection wavelength
of 254 nm. The mobile phase was a mixture of acetonitrile,
water, and acetic acid (57:43:1). Themean of the dissolution
rate of two, three, or six tablets were evaluated, re-
spectively. The criterion was set that the dissolution rate of
candesartan cilexetil should be more than 75% at the 45-
minute sampling point.30
Handheld Raman spectroscopy. All tablets were exam-
inedwith ahandheldRamanspectrometer (TruScan®, Thermo
Fisher Scientiﬁc, Waltham, MA). The chemical equivalence
between the authentic reference product (tablets containing
8 mg API) and the collected samples was evaluated based
on the P value for similarity of the Raman spectra, which
was automatically calculated by the instrument’s built-in
algorithm, which has been validated, but not disclosed, and is
designed not to be modiﬁed. Next, the raw Raman data were
subjected to PCA analysis. Spectra components from the API
were obtainedby analysis of authentic tablets containing 0mg
(Placebo), 4 mg, 8 mg, and 12 mg of the API. The weight and
size of 0 mg (Placebo), 4 mg, 8 mg, and 12 mg tablets are
equivalent, and same weights of each excipient except lac-
tose monohydrate to adjust total weights of them.
Preprocessing of Raman spectra. The data interval of the
handheld device is around 1.4–2.2 cm−1 and the noise level
is high, so preprocessing of the spectroscopy spectra is
critical for accurate PCA calculation. We used the Savitzky–
Golay (SG) method45 to smooth each segment of the original
Raman spectrum in a small window by ﬁtting to a polynomial
function.45,46 The MSC method46–49 was also applied to
eliminate the baseline shift caused by the multiplication of the
baseline tilts and the additive shift of the baseline shifts up
and down.46–49 Multiplicative scattering correlation can use
data from many wavelengths to distinguish between light
absorption and light scattering, correcting spectra according
to a simple linear univariate ﬁt to a standard spectrum by
means of least-squares regression using the standard spec-
trum.47 The observed spectrum YðωÞ is considered to depend
on wavelength as follows:
FIGURE 2. Comparison of dissolution rate (%) for the samples collected in China and Myanmar. The vertical dashed line shows the acceptance
criteria should be more than 75% dissolution rate at 45-minute sampling time. This ﬁgure appears in color at www.ajtmh.org.
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YðωÞ¼YðωÞþ aωþbþ eðωÞ; (1.1)
where, YðωÞ is the standard spectrum and eðωÞ represents
the residual. a and b are adjusted to minimize the term of e(ω),
to make these discrete deviations as small as possible.47
Principal component analysis. The Unscrambler® X soft-
ware (CAMO Software, Oslo, Norway) was used for PCA. The
Raman spectra data set consisting of 85 samples and 476
wavenumbers was calculated and it was decomposed into a
linear combination of score tn and loading pn consisting of sev-
eral principal components, allowing the spectrum to be un-
derstood clearly with a limited number of principal components.
That is, thedatasetX is decomposed intoa linear combinationof
the score and the loading as shown in equation (1.2).
X¼ t1p1þ t2p2þ t3p3þ/tNpN (1.2)
The validity and robustness of the calculated PCA model
were conﬁrmed by cross-random validation.
RESULTS
Table 1 shows the summary of collected samples from
China, Indonesia, and Myanmar. More than 15 brands of
candesartan cilexetil tablets are available in China, as judged
from an internet survey, but only four were found to be dis-
tributed in hospitals and clinics in Shanghai. The products
distributed in Shanghai in China were from manufacturers in
China and Japan. On the other hand, three brands, manu-
factured in Japan, India, and Pakistan, were found in private
hospitals, community pharmacies, and wholesalers in Man-
dalay, Myanmar. No obvious deﬁciencies in the PTP pack-
aging, package insert for use, pillows, or tablets were found in
visual inspection of all collected samples.
Content uniformity, assay and dissolution. Table 2
summarizes the results of the content uniformity, assay, and
dissolution tests of collected samples. The assay values of 12
of 13 samples of the tablets stated as XINXIN candesartan
cilexetil tablets exceeded the upper limit of 105.0%. Two
samples stated as悉君宁 and one sample stated as Advant
candesartan cilexetil tablets gave an assay value less than the
lower acceptance limit of 95.0% as shown in Figure 1. Dis-
solution delay was conﬁrmed in two samples of XINXIN can-
desartan cilexetil tablets, which failed to meet the criterion
dissolution rate of more than 75% at 45 minutes as shown in
Figure 2. Other tablets met the criterion.
Handheld Raman spectroscopy and PCA. Raman spec-
tra obtained with the handheld instrument are shown in
Figure 3. The spectral features are mainly due to the API and
the excipients, including lactose monohydrate. The Raman
FIGURE 3. Ramanspectra of candesartan cilexcetil tablets and the falsiﬁedproducts (beforemultiplicative scatteringcorrelationpreprocessingof
Raman spectra). This ﬁgure appears in color at www.ajtmh.org.
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spectra of the falsiﬁed products and products stated as
XINXIN showed a distinctive upward slop of the baseline to-
ward high wavenumber. The API peak intensity in this region
was reported to increase linearly with the increase in API
content in the tablets,34,50 and a similar result was also
obtained in this study. These relationships of the quantitation
between the API peak intensity and the assay of the API in
tablet were also conﬁrmed in not only the weight measure-
ment ofAPI versus thepeak intensityofRamanspectrabut also
the relationship between the weight measurement of API ver-
sus the peak intensity of X-ray diffraction measurement.50
These Raman spectra were conducted preprocessing and
subjected to PCA to investigate the similarity of chemical
components among samples. Figure 4 shows the spectra
after the preprocessing of SGmethod for smoothing andMSC
method for baseline correction for the Raman spectra. The
calibration result and the cross-validation result in the PCA
model were compared as shown in Figure 5. The result sug-
gested that the difference among the samples can be clariﬁed
by using the two principal components of PC1 and PC2, and
the intensity change of Raman spectrum can be sufﬁciently
expressed by PC1 and PC2. Therefore, the score plot was
shown with the score of the PC1 and PC2 on the horizontal
axis and the vertical axis and the vertical axis, respectively, for
each tablet as shown in Figure 6. Data set of the Raman
spectra in the rangeof 1780–1700 cm−1, which includespeaks
from the API and main excipient6s, showed the intuitive in-
terpretation score plot in the PCA result. Tablets collected in
Myanmar were distributed around authentic Blopress tablets
in the score plot, suggesting that the similar excipients were
used in both cases. On the other hand, the tablets collected in
China showed a wide distribution on the score plot, sug-
gesting that different excipients were used by different man-
ufacturers. Notably, the tablets stated as XINXIN were placed
very far from the other tablets and there was a high positive
correlation in PC1, and the falsiﬁed products collected in
Indonesia were located similarly in the plot. The falsiﬁed
products included the API but clearly insufﬁcient assay of the
dose displayed on the package (16 mg), as judged from both
the Raman spectra and the PC2 correlation compared with
FIGURE 4. Raman spectra of candesartan cilexetil tablets and the falsiﬁed products (after multiplicative scattering correlation preprocessing of
Raman spectra). This ﬁgure appears in color at www.ajtmh.org.
FIGURE 5. Comparison between the calibration model and valida-
tion result in principal component analysis model. This ﬁgure appears
in color at www.ajtmh.org.
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that of the authentic products. This result was in agreement
with the result of the additional assay measurement (assay:
about 60%) obtained using HPLC. In addition, both SFs
contained almost the same amount of API, despite being la-
beled on the packages as having 8 mg and 16 mg, re-
spectively, suggesting that these were falsiﬁed products with
poor quality control.
Figure 7 shows the loading of each principal component
(PC) in the calculated PCAmodel. The contribution rates were
84%of PC1, 7%of PC2, and 5%of PC3. PC2was shown as a
component that extracted the characteristics of the signal
derived from API, whereas PC1 showed the characteristics of
the excipients of the lactose and other excipients in the wave
number region of 1200–1000 cm−1. PC3 appeared to be
mainly due to lactose factor.
DISCUSSION
Candesartan cilexetil tablets distributed in China, Indo-
nesia, andMyanmarweremadeby variousmanufacturers and
contained different kinds of excipients. Testing identiﬁed a
number of samples with unacceptable API contents above or
below the criteria limit of the Japanese pharmacopeia, and
others with excessive dissolution delay. The failed samples
that did not meet the criteria were all located far from the
center in PCA score plot. Principal component analysis was
also very effective in distinguishing different excipients, which
appeared in different regions of the score plot. Principal
component analysis result was able to explain all spectra
clearlywith twocomponents, i.e., themedicinal ingredient and
the excipient, including lactose. ThePCA result decomposed
spectrum reﬂected the elements of pure Raman spectrum on
PC2 without interference by background of strong ﬂores-
cence substances. In this study, with an appropriate spectral
preprocessing and PCA combination, even in market re-
search using a large amount of Raman spectrum of various
kinds of tablets, including some unknown excipients, the
elements of the API and the kinds of the excipients are clearly
extracted, and the similarity and correlation are clearly
visualized.
A key feature of the present work was the use of the MSC
method for Raman signal preprocessing. This method proved
to be more effective than other commonly used methods,
such as the second derivative and standard normal variate
methods, for extracting the desired signals from the strong
ﬂuorescence background. It was found how to extract the
chemical information itself from the spectra of the spectro-
scope, not the experimental devices and methods, is a sig-
niﬁcant powerful and effective solution for detecting SFs.
These results suggest that the handheld Raman deice we
usedcould be a useful tool to detect SFs in the ﬁeld, despite its
relatively low sensitivity and low resolution.
In conclusion, the combination of pharmacopeial quality
control tests and PCA score plots calculated from Raman
spectra proved to be a very effective methodology for
detecting SFs. Application of this approach to candesartan
cilexetil tablets collected in several Asian countries uncovered
a number of examples of out-of-speciﬁcation content and
FIGURE 6. Principal component analysis score plot derived from theRamanspectra of candesartan cilexetil tablets, including the falsiﬁed tablets,
collected in China, Indonesia, Japan, and Myanmar. This ﬁgure appears in color at www.ajtmh.org.
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inadequate dissolution. The handheld Raman device is
expected to be useful in ﬁeld surveys to detect SFs. Principal
component analysis of that Raman data clarify the difference
in chemical properties between good quality products and
SFs that circulate in the Asian market.
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